Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 100.80% | -30.05% | 4.01% | -6.39% | -11.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.97% | 5.94% | 55.73% | -1.18% | 13.26% |
| Operating Income | -34.28% | -5.94% | 4.28% | 1.18% | 1.34% |
| Income Before Tax | -40.26% | -9.99% | 54.94% | -3.77% | -4.45% |
| Income Tax Expenses | -- | -- | 150.97% | -- | -- |
| Earnings from Continuing Operations | -38.10% | -9.99% | 49.10% | -3.77% | -6.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.10% | -9.99% | 49.10% | -3.77% | -6.09% |
| EBIT | -34.28% | -5.94% | 4.28% | 1.18% | 1.34% |
| EBITDA | -36.53% | -6.51% | 17.57% | 0.30% | 1.11% |
| EPS Basic | -33.64% | -5.80% | 50.53% | -0.72% | -3.64% |
| Normalized Basic EPS | -35.75% | -5.82% | 1.46% | -0.69% | -2.07% |
| EPS Diluted | -33.64% | -5.80% | 50.53% | -0.72% | -3.64% |
| Normalized Diluted EPS | -35.75% | -5.82% | 1.46% | -0.69% | -2.07% |
| Average Basic Shares Outstanding | 3.35% | 3.97% | 2.91% | 3.03% | 2.35% |
| Average Diluted Shares Outstanding | 3.35% | 3.97% | 2.91% | 3.03% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |